VivoSeq
Musculoskeletal

Osteoporosis

134

Pipeline Programs↗

29

Active Trials↗

54

Companies Involved↗

Osteoporosis is a highly competitive landscape with 134 programs across 54 companies. The most active players are Help Therapeutics, Ligand Pharmaceuticals, Takeda. 34 therapies are approved with 48 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

75/100

Pipeline Velocity

25/100

Mech. Concentration

14/100

Completion Rate

92/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Help Therapeutics

1 program

Phase 1L

Ligand Pharmaceuticals

1 program

Phase 2Takeda logo

Takeda

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2H

Hikma Pharmaceuticals LLC

1 program

Phase 2Biogen logo

Biogen

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical17

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Calcium Carbonate

Otsuka

Melatonin

Neurim Pharmaceuticals Ltd.

Pyridoxine

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Calcium

Eli Lilly

Phase 15

Sotatercept

Merck & Co.

Allorx

The Foundation for Orthopaedics and Regenerative Medicine

Blackcurrant (BC) Extract

University of Connecticut

Edirol

Shinshu University

Gu-Sui-Bu (davallia Divaricata)

National Taiwan University Hospital

Phase 230

Atenolol

Twinpig Biolab, Inc.

Letrozole

Novartis

Dasatinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Alendronate

Organon and Co

Pamidronate

Hikma Pharmaceuticals LLC

Phase 348

Medroxyprogesterone Acetate

Eli Lilly

Alfacalcidol

Roche

Tibolone

Pfizer

Metformin

EMD Serono

Risedronate

Vitae Pharmaceuticals Inc., an Allergan affiliate

Approved34

Estradiol

Novo Nordisk

Zoledronic Acid

Pfizer

Magnesium Sulfate

Fresenius Kabi Oncology Ltd.

Raloxifene

Eli Lilly

Levonorgestrel

Italian Network for Tumor Biotherapy Foundation

Analysis

Modality Breakdown

91%

Small molecule

150 of 165 classified programs — the dominant modality here.

9%ALL OTHERSMonoclonal antibody95%Protein / enzyme21%Peptide21%Cell therapy21%

Small molecule leads; the ring shows all 165 classified programs, each share of the total. Modality classified for 100% of 173 pipeline programs.

Analysis

Trial Status

263

clinical trials

Completed189 · 72%
Unknown status28 · 11%
Recruiting16 · 6%
Terminated11 · 4%
Active, not recruiting8 · 3%
Withdrawn5 · 2%
Other6 · 2%

Clinical Trials

Trial Activity

263 trials

RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis
Recruiting·PPrince of Wales Hospital, Shatin, Hong Kong·Phase 4·NCT06643780·120 enrolled
A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis
Recruiting·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 3·NCT06804590·278 enrolled
Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients
Recruiting·SShinshu University·Phase 2·NCT03755193·90 enrolled
A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures
Recruiting·OOdense University Hospital·Phase 4·NCT06864130·1,400 enrolled
Biobank for Inflammatory Chronic Diseases and Osteoporosis
Recruiting·UUniversity Hospital, Toulouse·N/A·NCT05039216·2,000 enrolled
Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis
Recruiting·—·Phase 3·NCT04704947·50 enrolled
Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover
Recruiting·—·Phase 4·NCT05151484·60 enrolled
Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
Recruiting·SShanghai Jiao Tong University Affiliated Sixth People's Hospital·Phase 4·NCT05902078·300 enrolled
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
Recruiting·Amgen logoAmgen·Phase 4·NCT06588153·100 enrolled
Preserving Geriatric Muscle With an Osteoporosis Medication
Recruiting·—·Phase 4·NCT06118905·155 enrolled
Step-down Therapy After Long-term Osteoporosis Treatment
Recruiting·NNational Taiwan University Hospital·Phase 4·NCT07281586·44 enrolled
The Optimised Use of Romozosumab Study
Recruiting·UUniversity of Aarhus·Approved·NCT06059222·270 enrolled
Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
Recruiting·KKanuni Sultan Suleyman Training and Research Hospital·N/A·NCT07677072·98 enrolled
Functional Muscle-Bone Incongruity Index (FKUI): Combined Evaluation of Handgrip Strength, Total Hip Bone Mineral Density, and Lumbar-Hip Bone Mineral Density Discordance in Adults Undergoing DXA
Recruiting·KKanuni Sultan Suleyman Training and Research Hospital·N/A·NCT07677033·200 enrolled
The Clinical Investigation to Evaluate the Safety and Efficacy of Vessel-X® Bone Filling Container System
Recruiting·—·Preclinical·NCT07665424·146 enrolled
Page 1 of 18

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)